Post-hoc analysis of the primary prevention subgroup of DECLARE-TIMI 58 suggests that treatment with dapagliflozin may reduce the risk for first heart failure and renal events.
People with type 2 diabetes, particularly those diagnosed at a young age, can face an extended wait for medication to treat cardiovascular risk factors, even if they are in a high-risk category, research shows.
A network meta-analysis highlights the impact of individual risk profiles on the absolute benefits offered by GLP-1 receptor agonists and SGLT2 inhibitors for people with type 2 diabetes.